NTAGI approves Covovax Covid-19 vaccine for the 12-17 age group
The National Immunization Technical Advisory Group (NTAGI) has approved the Covovax Covid-19 vaccine for the 12-17 age group. Produced by the Serum Institute of India, the Covovax vaccination course consists of two separate doses of 0.5 ml each. The second dose is to be administered 3 weeks after the first dose. The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.
01:27- 01:16
- 02:53
- 05:33
- 01:06
- 07:26
- 02:26
- 01:15
- 04:11
- 01:01
India reels under intense heatwave
Views: 181 - 06:07
- 06:08
- 04:42
- 02:24
- 02:56
- 02:00
- 03:40
- 03:28
- 01:16
- 01:58
- 01:59
- 06:57
- 01:11
- 07:24
- 05:56
- 01:30
- 02:10
- 02:28
- 01:54
- 02:30
- 02:32
- 00:32
- 02:42
- 01:24
- 01:11
- 03:41
- 04:25
- 05:02
- 02:26
Power failure in parts of Mumbai, Thane
Views: 447
